Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
AstraZeneca
ViroMissile, Inc.
EMD Serono
Arcus Biosciences, Inc.
Seagen Inc.
Pfizer
Tizona Therapeutics, Inc
Genentech, Inc.
USWM, LLC (dba US WorldMeds)
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
SN BioScience
Qilu Pharmaceutical Co., Ltd.
Innate Pharma
GlaxoSmithKline
HiFiBiO Therapeutics
AbbVie
Actym Therapeutics, Inc.
Nurix Therapeutics, Inc.
3B Pharmaceuticals GmbH
Exelixis
Jonsson Comprehensive Cancer Center
Incyte Corporation
Pfizer
Columbia University
Seagen Inc.
Immatics US, Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Symphogen A/S
Acepodia Biotech, Inc.
TopAlliance Biosciences
Inhibrx Biosciences, Inc
NGM Biopharmaceuticals, Inc
Taiho Pharmaceutical Co., Ltd.
Xencor, Inc.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Adaptimmune
Ipsen
Merck Sharp & Dohme LLC
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Genzada Pharmaceuticals USA, Inc.
Xencor, Inc.